Basilea Wins $130 Million in Dispute Over J and J’s Conduct of Pivotal Trials

A tribunal at the Netherlands Arbitration Institute has ruled Johnson & Johnson (J&J) must pay Basilea Pharmaceutica $130 million to compensate for improperly conducted pivotal trials for the antibiotic ceftobiprole that Basilea says have prevented the drug’s approval. The tribunal found J&J in breach of a license agreement it signed with Switzerland-based Basilea in 2005 that gave J&J worldwide rights for the development, manufacture and commercialization of ceftobiprole, Basilea said.

Clinical Trials Advisor

http://www.fdanews.com/newsletter/article?issueId=14295&articleId=132631

http://www.depsyl.com/

http://back2basicnutrition.com/

http://bionutritionalresearch.olhblogspace.com/